Last reviewed · How we verify

Diclofenac Capsules low dose — Competitive Intelligence Brief

Diclofenac Capsules low dose (Diclofenac Capsules low dose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NSAID. Area: Rheumatology.

phase 2 NSAID COX-2 Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

Diclofenac Capsules low dose (Diclofenac Capsules low dose) — Iroko Pharmaceuticals, LLC. Diclofenac works by inhibiting the enzyme cyclooxygenase (COX), which is involved in the production of prostaglandins, leading to reduced inflammation and pain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Diclofenac Capsules low dose TARGET Diclofenac Capsules low dose Iroko Pharmaceuticals, LLC phase 2 NSAID COX-2
Celebrex celecoxib Pfizer Inc. (originally Searle/Pharmacia) marketed Nonsteroidal Anti-inflammatory Drug [EPC] COX-2 1998-12-31
Cytotec Misoprostol Pfizer marketed NSAID combined with prostaglandin analog Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors 1988-01-01
Dexketoprofen Trometamol + Paracetamol Dexketoprofen Trometamol + Paracetamol Yuzuncu Yil University marketed NSAID + analgesic combination COX-1, COX-2 (dexketoprofen); central prostaglandin synthesis and pain pathways (paracetamol)
NSAID (Aceclofenac) NSAID (Aceclofenac) Dong-A ST Co., Ltd. marketed NSAID (nonsteroidal anti-inflammatory drug) COX-1, COX-2
Naproxen Sodium + Codeine Phosphate Naproxen Sodium + Codeine Phosphate ibrahim doğru marketed NSAID + opioid analgesic combination COX-1, COX-2, mu-opioid receptor
Dexketoprofen Trometamol + Thiocolchicoside Dexketoprofen Trometamol + Thiocolchicoside Yuzuncu Yil University marketed NSAID + muscle relaxant combination COX-1/COX-2 (dexketoprofen); GABA receptors and microtubule dynamics (thiocolchicoside)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (NSAID class)

  1. Antibe Therapeutics Inc. · 3 drugs in this class
  2. Iroko Pharmaceuticals, LLC · 3 drugs in this class
  3. Organon and Co · 2 drugs in this class
  4. Apsen Farmaceutica S.A. · 2 drugs in this class
  5. Amneal Pharmaceuticals, LLC · 2 drugs in this class
  6. Behar, Caren, M.D. · 2 drugs in this class
  7. IDEA AG · 2 drugs in this class
  8. Noven Pharmaceuticals, Inc. · 2 drugs in this class
  9. HALEON · 2 drugs in this class
  10. Pfizer · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Diclofenac Capsules low dose — Competitive Intelligence Brief. https://druglandscape.com/ci/diclofenac-capsules-low-dose. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: